The Medical Advisor

The spike protein is naturally found in SARS-CoV-2, no matter the variant. In its native form in SARS-CoV-2, the spike protein is responsible for the pathologies of the viral infection. In its wild form it’s known to open the blood-brain barrier, cause cell damage (cytotoxicity) and, as Dr. Robert Malone, the inventor of the  mRNA and DNA vaccine core platform technology , said in a commentary on  News Voice , “is active in manipulating the biology of the cells that coat the inside of your blood vessels — vascular endothelial cells, in part through its interaction with ACE2, which controls contraction in the blood vessels, blood pressure and other things.” It’s also been revealed that the spike protein on its own is enough to cause inflammation and damage to the vascular system, even independent of a virus. ( R )  Base Spike Detox According to Dr Peter McCullough (in a Twitter post): Base Spike Detox is what I am currently using in my practice for those who have had ...

Abstract Butyrate , a short-chain fatty acid (SCFA) produced via bacterial fermentation of dietary fiber in the colon, has emerged as a critical modulator of gut health, immune regulation, and neurocognitive function. This review explores the metabolic, immunological, and neurological roles of butyrate, examining its mechanisms of action and implications for chronic disease prevention. Current evidence underscores the necessity of dietary and lifestyle interventions to enhance butyrate production and optimize overall health outcomes. Introduction Butyrate, one of the principal SCFAs generated by gut microbiota, plays a fundamental role in maintaining colonic homeostasis, regulating immune responses, and supporting neural function. Recent studies have emphasized its influence on metabolic pathways, immune modulation, and the gut-brain axis. Understanding butyrate’s diverse physiological roles is essential for advancing therapeutic strategies targeting gut dysbiosis, inflammatory disorde...

Probiotics are a combination of live microorganisms, while prebiotics are non-digestible food ingredients. Both probiotics and prebiotics are essential for digestive health and overall wellness. Probiotics help to promote the growth of beneficial bacteria in the gut, while prebiotics can help to feed those beneficial bacteria and support a healthy balance of bacteria in the digestive tract.  The Connection Between Gut Inflammation and Weight Gain Gut health is one factor that affects inflammation. An unbalanced microbiota adds to the type of inflammation that supports weight gain and fluid retention, which makes losing weight extremely difficult. This is why rebalancing gut microbes become one of the main keys to weight management which can be helped by probiotics. Lactobacillus Gasseri and Weight Loss Lactobacillus gasseri, of all the probiotic bacteria examined so far, shows some of the most promising weight-loss effects. It has been shown in numerous animal experiments that it h...

Probiotics are living microorganisms that offer lots of health benefits if consumed in sufficient amounts, such as balancing the “good” bacteria in your digestive system, strengthening immune system, and lowering the risk and severity of diarrhoea. Many studies also linked probiotics with improvement in mental health conditions such as anxiety, depression, and stress. The global gut health is predicted to grow by around 8% annually at least to the end of the decade. There are a number of factors combining to drive growth in the gut and digestive health market. One is that consumers are increasingly aware of the importance of gut health and comfort, and that they can, to some extent, manage that themselves through food choices and supplements. This is linked to the fact that global populations are ageing, and more and more people are living with chronic gastric disorders. At the same time, scientists are gaining better understanding of both the importance of the gut (microbiome) on huma...

Abstract Drug repurposing continues to gain momentum as a time- and cost-effective strategy to expand therapeutic options in oncology. By leveraging established pharmacokinetic, safety, and manufacturing data of approved non-cancer drugs, repurposing can reduce development timelines from 10–15 years to 5–7 years and costs by 60–80%. This updated review, building on the comprehensive 2024 analysis by Ying Xia et al.  (Nature 2024), incorporates major advances reported between mid-2024 and November 2025. Key developments include: maturation of artificial intelligence (AI)-driven discovery platforms, new Phase II/III clinical trial readouts for metformin, mebendazole, itraconazole, disulfiram, and atovaquone, expanding evidence for tumor microenvironment (TME) modulation, improved nanoformulations, and emerging precision-repurposing frameworks using single-cell and spatial omics. We provide a hallmark- and TME-centric fr...